

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1057105
<b>Application Number:</b>	09889227
<b>Confirmation Number:</b>	5714
<b>Title of Invention:</b>	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Pamela Richardson
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 15(1)
<b>Receipt Date:</b>	24-MAY-2006
<b>Filing Date:</b>	08-JAN-2002
<b>Time Stamp:</b>	16:56:28
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	NPL Documents	DumasRecentdevelopments.pdf	1279668	no	17

<b>Warnings:</b>					
<b>Information:</b>					
2	NPL Documents	DumasSynthesisandpharmacological.pdf	337191	no	4
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	EisenetalPhaseItrialofBAY.pdf	66103	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	EisenhaueretalImpactofnewnon-cytotoxics.pdf	512335	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	EscudieretalRandomizedPhaseIII.pdf	71404	no	1
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	factsandcomparison.pdf	662046	no	4
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Garcia-LopezetalNewroutes.pdf	42766	no	1
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	GeigeretalAntitumoractivity.pdf	545816	no	7
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Greigeretal.pdf	528068	no	7
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	HansonInhibitorsofph38kinase.pdf	49863	no	1

<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	HansonPulmonary-Allergy.pdf	291872	no	5
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	HeimetalAntitumoreffect.pdf	157173	no	2
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Hotteetal.pdf	393065	no	5
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	HotteetalBAY43-9006.pdf	393995	no	5
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	HubbardOncogenicMutations.pdf	318340	no	3
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Iwadateetal.pdf	96571	no	2
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	JeffcoatetalTheMetabolism.pdf	640778	no	10
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	KemperetalSynthesepotentieller.pdf	1396625	no	20
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Khireetal.pdf	262018	no	4

**Warnings:****Information:**

20	NPL Documents	Kuboetal.pdf	173337	no	1
----	---------------	--------------	--------	----	---

**Warnings:****Information:**

<b>Total Files Size (in bytes):</b>	8219034
-------------------------------------	---------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.